Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17403978 | 1.00 | BTN3A1 (0.52) | BTN3A1NPC1RAB9AELANEHTR2A | |
| SCHEMBL18953048 | 1.00 | BTN3A1 (0.52) | BTN3A1NPC1RAB9AELANEHTR2A | |
| SCHEMBL26295789 | 0.91 | NPC1 (0.48) | BTN3A1NPC1RAB9AELANEHTR2A | |
| SCHEMBL17550480 | 0.90 | BTN3A1 (0.44) | BTN3A1NPC1RAB9AELANEHTR2A | |
| SCHEMBL12621314 | 0.89 | NPC1 (0.46) | BTN3A1NPC1RAB9AELANEHTR2A | |
| SCHEMBL30089933 | 0.89 | BTN3A1 (0.50) | BTN3A1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL10149592 | 0.89 | BTN3A1 (0.50) | BTN3A1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL28854863 | 0.89 | BTN3A1 (0.50) | BTN3A1NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL23818599 | 0.88 | NPC1 (0.48) | BTN3A1NPC1RAB9AHTR2AALDH1A1 | |
| SCHEMBL18973549 | 0.88 | BTN3A1 (0.60) | BTN3A1ELANEALDH1A1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-05-19 | — | — | US | disclosed |
| CN-110590839-A | Levatinib derivative and preparation method and application thereof | 四川海思科制药有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2019-04-04 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
| WO-2017098252-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES AND OF THE GEMCITABINE PRODRUG NUC-1031 | NUCANA BIOMED LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | BTN3A1 1653/4885NPC1 2683/4885RAB9A 3170/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | BTN3A1 4156/4885NPC1 91/4885RAB9A 620/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | BTN3A1 4597/4885NPC1 343/4885RAB9A 678/4885 |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885NPC1 2136/4885RAB9A 2825/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | BTN3A1 4597/4885NPC1 343/4885RAB9A 678/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | BTN3A1 4597/4885NPC1 343/4885RAB9A 678/4885 |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | BTN3A1 1681/4885NPC1 2596/4885RAB9A 3082/4885 |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, NT5C, DUT | BTN3A1 1561/4885NPC1 3075/4885RAB9A 3469/4885 |
| US-10654877-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | BTN3A1 1653/4885NPC1 2683/4885RAB9A 3170/4885 |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NT5C | BTN3A1 1544/4885NPC1 2729/4885RAB9A 3136/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | BTN3A1 1653/4885NPC1 2683/4885RAB9A 3170/4885 |
| US-20200181190-A1 | SYNTHESIS OF 3'-DEOXYADENOSINE-5'-O-[PHENYL(BENZYLOXY-L-ALANINYL)]PHOSPHATE (NUC-7738) | PNP, NT5C2, DUT | BTN3A1 3995/4885NPC1 1005/4885RAB9A 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.